xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06014502</url>
    </required_header>
    <id_info>
      <org_study_id>IMGS-001-011</org_study_id>
      <nct_id>NCT06014502</nct_id>
    </id_info>
    <brief_title>Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors</brief_title>
    <official_title>A Phase 1a/1b, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMGS-001 in Patients With Relapsed or Refractory Advanced Solid Tumors</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>ImmunoGenesis</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>ImmunoGenesis</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The purpose of this Phase 1a/1b clinical trial is to test the safety of an investigational&#xD;
        drug called IMGS-001 and to determine how well it can work in treating patients with advanced&#xD;
        solid tumors that have come back or are not improving after receiving other drugs that are&#xD;
        commonly used for their cancer. Phase 1a (Part 1) will test the safety of five different&#xD;
        doses of IMGS-001 to use in further studies. Patients with cancer that have advanced or&#xD;
        spread to other parts of the body following treatment with other available therapies will be&#xD;
        treated in Part 1. Phase 1b (Part 2) will test two doses of IMGS-001 identified in Part 1 to&#xD;
        further determine the safety and potential effectiveness in select cancer types.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Part 1 is a Phase 1a, first-in-human, open-label dose-escalation study to determine the&#xD;
        safety, tolerability, and maximum tolerated dose (MTD) of IMGS-001. The safety, tolerability,&#xD;
        PK parameters, and preliminary antitumor activity of IMGS-001 will be assessed in adult&#xD;
        patients with advanced solid tumors refractory to appropriate standard of care (SOC)&#xD;
        treatments.&#xD;
  &#xD;
        Based on the MTD and other information (e.g., tolerability, PK, PD, target engagement), two&#xD;
        doses of IMGS-001 will be selected for further evaluation. Additional subjects will be&#xD;
        backfilled until at least 10 evaluable subjects have been treated with each of these doses.&#xD;
        Approximately 25 total subjects will be enrolled in Phase 1a.&#xD;
  &#xD;
        Part 2 is a Phase 1b, open-label, dose-expansion study of five prespecified tumor cohorts to&#xD;
        assess preliminary antitumor activity of IMGS-001 in patients that are refractory or&#xD;
        intolerant to other appropriate prior standard therapies. Eligible patients must have&#xD;
        confirmed PD-L1 expression. To meet PD-L1 expression eligibility in Phase 1b, patients must&#xD;
        have confirmed PD-L1 expression (combined positive score (CPS) ≥ 5 or tumor proportion score&#xD;
        (TPS) ≥ 5%). Initially, up to 10 subjects in each of the following cohorts will be treated:&#xD;
  &#xD;
        Cohort 1: Ovarian cancer; Cohort 2: Colorectal cancer; Cohort 3: Triple-negative breast&#xD;
        cancer; Cohort 4: Bladder cancer; Cohort 5: Gastric or esophageal cancer (gastroesophageal&#xD;
        junction (GEJ) or esophageal adenocarcinoma).&#xD;
  &#xD;
        Each cohort will be assessed to meet efficacy criteria to continue into a randomized&#xD;
        dose-optimization. Within each cohort that meets prespecified efficacy criteria, the expanded&#xD;
        cohorts will have randomly assigned (1:1) subjects to receive one of two doses used in the&#xD;
        Phase 1a. Within each Arm, 20 eligible subjects will be treated with the assigned dose of&#xD;
        IMGS-001.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date type="Anticipated">August 2023</start_date>
    <completion_date type="Anticipated">December 2027</completion_date>
    <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
    <phase>Phase 1</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Non-Randomized</allocation>
      <intervention_model>Sequential Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Phase 1a- Safety and tolerability of IMGS-001 by dose-limiting toxicities and adverse events</measure>
      <time_frame>21 days</time_frame>
      <description>Frequency and severity of dose limiting toxicities and adverse events</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Phase 1b- Recommended Phase 2 dose (RP2D) of IMGS-001 for specified tumor-specific cohorts as a pharmacologically optimal dose (POD)</measure>
      <time_frame>12 months</time_frame>
      <description>RP2D will be defined by pooling all available PK, PD, target engagement, efficacy, safety, and tolerability data from Part 1 and Part 2</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Phase 1a- Maximum tolerable dose (MTD) of IMGS-001</measure>
      <time_frame>12 months</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetics (PK) of IMGS-001 by terminal half life (t1/2)</measure>
      <time_frame>12 months</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetics (PK) of IMGS-001 by Area Under the Curve (AUC)</measure>
      <time_frame>12 months</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetics (PK) of IMGS-001 by Maximum Observed Concentration (Cmax)</measure>
      <time_frame>12 months</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pharmacokinetics (PK) of IMGS-001 by Minimum Observed Concentration (Cmin)</measure>
      <time_frame>12 months</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Potential immunogenicity of IMGS-001 by measurement of positive anti-drug antibody (ADA) levels</measure>
      <time_frame>12 months</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Efficacy of IMGS-001 by Objective Response Rate (ORR) via iRECIST</measure>
      <time_frame>12 months</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Efficacy of IMGS-001 by Progression Free Survival (PFS)</measure>
      <time_frame>12 months</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Efficacy of IMGS-001 by Duration of Response (DOR)</measure>
      <time_frame>12 months</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Efficacy of IMGS-001 by Clinical Benefit Rate (CBR)</measure>
      <time_frame>12 months</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Phase 1b- Safety and tolerability of IMGS-001 by frequency and severity of Adverse Events</measure>
      <time_frame>12 months</time_frame>
    </secondary_outcome>
    <number_of_arms>6</number_of_arms>
    <enrollment type="Anticipated">105</enrollment>
    <condition>Solid Tumor</condition>
    <arm_group>
      <arm_group_label>Phase 1a Solid Tumors</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>IMGS-001 will be administered in escalating doses, with a starting dose of 0.3 mg/kg every 2 weeks escalating up to a maximum dose of 15 mg/kg.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Phase 1b Ovarian Cancer</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Phase 1b Colorectal Cancer</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Phase 1b Triple-negative Breast Cancer</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Phase 1b Bladder Cancer</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Phase 1b Gastric or Esophageal Cancer</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>IMGS-001</intervention_name>
      <description>Every 2 weeks</description>
      <arm_group_label>Phase 1a Solid Tumors</arm_group_label>
      <arm_group_label>Phase 1b Bladder Cancer</arm_group_label>
      <arm_group_label>Phase 1b Colorectal Cancer</arm_group_label>
      <arm_group_label>Phase 1b Gastric or Esophageal Cancer</arm_group_label>
      <arm_group_label>Phase 1b Ovarian Cancer</arm_group_label>
      <arm_group_label>Phase 1b Triple-negative Breast Cancer</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Part 1 Dose-escalation: Patients must have histologically confirmed locally advanced,&#xD;
               or metastatic solid tumors who have progressed after receiving appropriate lines of&#xD;
               standard therapy known to potentially confer clinical benefit.&#xD;
  &#xD;
            -  Part 2 Dose-expansion: Patients must have histologically confirmed locally advanced,&#xD;
               or metastatic cancer in one of the following pre-specified tumor types and meet&#xD;
               tumor-specific criteria:&#xD;
  &#xD;
                 1. Ovarian: Failed or intolerant to prior lines of appropriate standard of care&#xD;
                    chemotherapy and targeted therapy regimens. Must be naïve to treatment with PD-1&#xD;
                    and PD-L1 targeting agents.&#xD;
  &#xD;
                 2. Colorectal: Failed or intolerant to prior lines of appropriate standard of care&#xD;
                    chemotherapy and targeted therapy regimens. Must be naïve to treatment with PD-1&#xD;
                    and PD-L1 targeting agents.&#xD;
  &#xD;
                 3. Triple-Negative Breast Cancer: Failed or intolerant to prior lines of appropriate&#xD;
                    standard of care chemotherapy and targeted therapy regimens. Failed, did not&#xD;
                    respond, or intolerant to prior immune checkpoint therapy (e.g., anti-PD-1).&#xD;
  &#xD;
                 4. Bladder: Failed or intolerant to prior lines of appropriate standard of care&#xD;
                    chemotherapy and targeted therapy regimens. Failed, did not respond, or&#xD;
                    intolerant to prior immune checkpoint therapy (e.g., anti-PD-L1).&#xD;
  &#xD;
                 5. Gastric/Esophageal: Failed or intolerant to prior lines of appropriate standard&#xD;
                    of care chemotherapy and targeted therapy regimens for either gastric or&#xD;
                    esophageal cancer (gastroesophageal junction [GEJ] or esophageal adenocarcinoma).&#xD;
                    Failed, did not respond, or intolerant to prior immune checkpoint therapy (e.g.,&#xD;
                    anti-PD-L1).&#xD;
  &#xD;
            -  Prostate cancer patients enrolled in Part 1 dose escalation must continue ongoing&#xD;
               androgen deprivation therapy with a gonadotropin-releasing hormone (GnRH) analog or&#xD;
               have undergone a bilateral orchiectomy (surgical or medical castration) and must have&#xD;
               a serum testosterone ≤1.73 nmol/L (50 ng/dL) at screening.&#xD;
  &#xD;
            -  Patients eligible to enroll in cohorts with prior immune checkpoint therapy must meet&#xD;
               the following criteria:&#xD;
  &#xD;
                 1. Received at least 2 doses of an approved or investigational anti PD-1 or&#xD;
                    anti-PD-L1 inhibitor.&#xD;
  &#xD;
                 2. Last dose of therapy must have been ≥ 28 days prior to Cycle 1 Day 1.&#xD;
  &#xD;
                 3. Eligible patients include those patients treated with anti PD-1/anti PD-L1 drugs&#xD;
                    who have progressed following response to prior therapy, and those that have&#xD;
                    failed to demonstrate any response to prior therapy.&#xD;
  &#xD;
            -  Patients participating in Part 2 (Phase 1b) must have confirmed PD-L1 positive&#xD;
               expression (CPS ≥ 5 or TPS ≥ 5%).&#xD;
  &#xD;
            -  Male or female ≥ 18 years of age.&#xD;
  &#xD;
            -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.&#xD;
  &#xD;
            -  Life expectancy &gt; 3 months.&#xD;
  &#xD;
            -  At least one measurable lesion as defined by iRECIST.&#xD;
  &#xD;
               a. A lesion that was previously irradiated may be considered a target lesion only if&#xD;
               it is measurable per iRECIST, has documented progression, and is clearly defined.&#xD;
  &#xD;
            -  Patients must have a non-target lesion that can be biopsied. If a patient only has one&#xD;
               target lesion (and no non-target lesions) the target lesion used for biopsy must be ≥&#xD;
               2 cm in longest diameter. Eligible subjects for biopsy must be clinically appropriate,&#xD;
               including specimens attainable and on appropriate subjects without presenting high&#xD;
               risk of major complications. Subjects in Phase 1a who are unable to undergo a biopsy&#xD;
               at screening must submit archival tumor tissue retrieved within the last 6 months.&#xD;
  &#xD;
            -  Patients must have adequate bone marrow and organ function as defined by:&#xD;
  &#xD;
                 1. Absolute neutrophil count (ANC) ≥ 1.5×10^9/L.&#xD;
  &#xD;
                 2. Platelet count of ≥ 100.0×10^9/L.&#xD;
  &#xD;
                 3. Hemoglobin of ≥ 9.0 g/dL.&#xD;
  &#xD;
                 4. Creatinine clearance ≥ 30 mL/min.&#xD;
  &#xD;
                 5. Liver function test: AST (SGOT) and ALT (SGPT) ≤ 2.5 times the institutional ULN.&#xD;
  &#xD;
                 6. Total bilirubin: ≤ 1.5 x ULN.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Receipt of any investigational or conventional anti-cancer drug/therapy within 21 days&#xD;
               of Cycle 1 Day 1.&#xD;
  &#xD;
            -  Current or prior use of immunosuppressive medication within 14 days of Cycle 1 Day 1.&#xD;
               Inhaled and intranasal corticosteroids are allowed.&#xD;
  &#xD;
            -  Current or prior use of interleukin-2, interferon, or other immunotherapy medication&#xD;
               within 28 days of Cycle 1 Day 1.&#xD;
  &#xD;
            -  Live vaccine within 28 days prior to Cycle 1 Day 1.&#xD;
  &#xD;
            -  Any toxicity from prior standard therapy that has not resolved to ≤ Grade 1 or&#xD;
               baseline per National Cancer Institute Common Terminology Criteria for Adverse Events&#xD;
               (NCI CTCAE) version 5.0 at the time of consent. Alopecia is an exception. Any patients&#xD;
               with irreversible Grade 1 or Grade 2 toxicities that are considered stable may be&#xD;
               enrolled after discussion with the Medical Monitor.&#xD;
  &#xD;
            -  Prior anti-PD-1 or anti-PD-L1-related Grade 3 or Grade 4 toxicity resulting in&#xD;
               treatment discontinuation of the drug.&#xD;
  &#xD;
            -  Secondary malignancy other than the target malignancy to be investigated in this trial&#xD;
               within the last 2 years.&#xD;
  &#xD;
            -  History of myocardial infarction, ischemic heart disease, symptomatic congestive heart&#xD;
               failure (New York Heart Association (NYHA) Class III IV), or significant cardiac&#xD;
               arrhythmias within 3 months of study enrollment.&#xD;
  &#xD;
            -  Arterial or venous thrombotic or embolic events such as cerebrovascular accident&#xD;
               (including transient ischemic attacks) or pulmonary embolism within 3 months of study&#xD;
               enrollment.&#xD;
  &#xD;
            -  History of acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI)&#xD;
               obstruction, abdominal carcinomatosis, bowel perforation, or other known risk factors&#xD;
               for bowel perforation.&#xD;
  &#xD;
            -  Active, uncontrolled, or prior documented autoimmune disorders including but not&#xD;
               limited to inflammatory bowel disease (including Crohn's disease and ulcerative&#xD;
               colitis), rheumatoid arthritis, systemic sclerosis (scleroderma), Systemic Lupus&#xD;
               Erythematosus, or autoimmune vasculitis (e.g., Wegener's Granulomatosis). Alopecia,&#xD;
               vitiligo, celiac disease controlled by diet, and chronic skin conditions not requiring&#xD;
               systemic therapy/immunosuppressive treatment is permitted.&#xD;
  &#xD;
            -  Uncontrolled intercurrent illness, including active infection requiring systemic&#xD;
               therapy, uncontrolled hypertension (&gt; 150/90mm Hg despite optimal medical management),&#xD;
               uncontrolled asthma, psychiatric illness/social situations, substance abuse, or other&#xD;
               underlying medical conditions that would limit compliance with study requirements,&#xD;
               obscure the interpretation of AEs, substantially increase the risk of developing AEs,&#xD;
               or make the administration of study treatment hazardous.&#xD;
  &#xD;
            -  Active human immunodeficiency virus (HIV) infection (Exception: patients with&#xD;
               well-controlled HIV [e.g., CD4 ≥ 350 cells/uL and undetectable viral load] who have&#xD;
               been on an effective [drug, dosage, and schedule associated with reduction and control&#xD;
               of the viral load] antiretroviral therapy [ART] for ≥ 4 weeks are eligible). Patients&#xD;
               with a history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic&#xD;
               infections in the last 12 months are not eligible.&#xD;
  &#xD;
            -  Active or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.&#xD;
               Patients with a history of HCV infection must have completed curative antiviral&#xD;
               treatment and must have a viral load below the limit of quantification. A patient who&#xD;
               is HCV antibody (Ab) positive but HCV RNA negative due to prior treatment or natural&#xD;
               resolution is eligible.&#xD;
  &#xD;
            -  History of solid organ transplantation.&#xD;
  &#xD;
            -  Newly diagnosed, uncontrolled, and/or untreated cancer-related central nervous system&#xD;
               disease. Patients with treated brain metastases that are radiographically or&#xD;
               clinically stable for at least 28 days after therapy and have no evidence of&#xD;
               cavitation or hemorrhage in the brain lesion(s) are eligible if they are asymptomatic&#xD;
               and do not require corticosteroids (the patient must have discontinued steroids at&#xD;
               least 14 days prior to Cycle 1 Day 1).&#xD;
  &#xD;
            -  Major surgery, open biopsy, or significant traumatic injury within 28 days of Cycle 1&#xD;
               Day 1, or still recovering from prior surgery. Port placement and other local&#xD;
               procedures are allowed if completed at least 48 hours prior to Cycle 1 Day 1.&#xD;
  &#xD;
            -  Prior history of pneumonitis or interstitial lung disease that required steroids or&#xD;
               who currently have pneumonitis or interstitial lung disease.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_contact>
      <last_name>Charles Schweizer, PhD</last_name>
      <phone>346-772-0336</phone>
      <email>charles.schweizer@immunogenesis.com</email>
    </overall_contact>
    <location>
      <facility>
        <name>MD Anderson Cancer Center</name>
        <address>
          <city>Houston</city>
          <state>Texas</state>
          <zip>77030</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Ly Nguyen</last_name>
        <phone>713-563-2169</phone>
        <email>LMNguyen1@mdanderson.org</email>
      </contact>
      <investigator>
        <last_name>David S. Hong, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 17, 2023</study_first_submitted>
    <study_first_submitted_qc>August 23, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 28, 2023</study_first_posted>
    <last_update_submitted>August 23, 2023</last_update_submitted>
    <last_update_submitted_qc>August 23, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 28, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Neoplasms</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06014502
  org study id: IMGS-001-011
  nct id: NCT06014502
  lead sponsor: 
  has dmc: Yes
  is fda regulated drug: Yes
  is fda regulated device: No
  The purpose of this Phase 1a/1b clinical trial is to test the safety of an investigational
        drug called IMGS-001 and to determine how well it can work in treating patients with advanced
        solid tumors that have come back or are not improving after receiving other drugs that are
        commonly used for their cancer. Phase 1a (Part 1) will test the safety of five different
        doses of IMGS-001 to use in further studies. Patients with cancer that have advanced or
        spread to other parts of the body following treatment with other available therapies will be
        treated in Part 1. Phase 1b (Part 2) will test two doses of IMGS-001 identified in Part 1 to
        further determine the safety and potential effectiveness in select cancer types.
  Part 1 is a Phase 1a, first-in-human, open-label dose-escalation study to determine the
        safety, tolerability, and maximum tolerated dose (MTD) of IMGS-001. The safety, tolerability,
        PK parameters, and preliminary antitumor activity of IMGS-001 will be assessed in adult
        patients with advanced solid tumors refractory to appropriate standard of care (SOC)
        treatments.
  
        Based on the MTD and other information (e.g., tolerability, PK, PD, target engagement), two
        doses of IMGS-001 will be selected for further evaluation. Additional subjects will be
        backfilled until at least 10 evaluable subjects have been treated with each of these doses.
        Approximately 25 total subjects will be enrolled in Phase 1a.
  
        Part 2 is a Phase 1b, open-label, dose-expansion study of five prespecified tumor cohorts to
        assess preliminary antitumor activity of IMGS-001 in patients that are refractory or
        intolerant to other appropriate prior standard therapies. Eligible patients must have
        confirmed PD-L1 expression. To meet PD-L1 expression eligibility in Phase 1b, patients must
        have confirmed PD-L1 expression (combined positive score (CPS) ≥ 5 or tumor proportion score
        (TPS) ≥ 5%). Initially, up to 10 subjects in each of the following cohorts will be treated:
  
        Cohort 1: Ovarian cancer; Cohort 2: Colorectal cancer; Cohort 3: Triple-negative breast
        cancer; Cohort 4: Bladder cancer; Cohort 5: Gastric or esophageal cancer (gastroesophageal
        junction (GEJ) or esophageal adenocarcinoma).
  
        Each cohort will be assessed to meet efficacy criteria to continue into a randomized
        dose-optimization. Within each cohort that meets prespecified efficacy criteria, the expanded
        cohorts will have randomly assigned (1:1) subjects to receive one of two doses used in the
        Phase 1a. Within each Arm, 20 eligible subjects will be treated with the assigned dose of
        IMGS-001.
  allocation: Non-Randomized
  intervention model: Sequential Assignment
  primary purpose: Treatment
  masking: None (Open Label)
  measure: Phase 1a- Safety and tolerability of IMGS-001 by dose-limiting toxicities and adverse events
  time frame: 21 days
  description: Frequency and severity of dose limiting toxicities and adverse events
  measure: Phase 1b- Recommended Phase 2 dose (RP2D) of IMGS-001 for specified tumor-specific cohorts as a pharmacologically optimal dose (POD)
  time frame: 12 months
  description: RP2D will be defined by pooling all available PK, PD, target engagement, efficacy, safety, and tolerability data from Part 1 and Part 2
  measure: Phase 1a- Maximum tolerable dose (MTD) of IMGS-001
  time frame: 12 months
  measure: Pharmacokinetics (PK) of IMGS-001 by terminal half life (t1/2)
  time frame: 12 months
  measure: Pharmacokinetics (PK) of IMGS-001 by Area Under the Curve (AUC)
  time frame: 12 months
  measure: Pharmacokinetics (PK) of IMGS-001 by Maximum Observed Concentration (Cmax)
  time frame: 12 months
  measure: Pharmacokinetics (PK) of IMGS-001 by Minimum Observed Concentration (Cmin)
  time frame: 12 months
  measure: Potential immunogenicity of IMGS-001 by measurement of positive anti-drug antibody (ADA) levels
  time frame: 12 months
  measure: Efficacy of IMGS-001 by Objective Response Rate (ORR) via iRECIST
  time frame: 12 months
  measure: Efficacy of IMGS-001 by Progression Free Survival (PFS)
  time frame: 12 months
  measure: Efficacy of IMGS-001 by Duration of Response (DOR)
  time frame: 12 months
  measure: Efficacy of IMGS-001 by Clinical Benefit Rate (CBR)
  time frame: 12 months
  measure: Phase 1b- Safety and tolerability of IMGS-001 by frequency and severity of Adverse Events
  time frame: 12 months
  arm group label: Phase 1a Solid Tumors
  arm group type: Experimental
  description: IMGS-001 will be administered in escalating doses, with a starting dose of 0.3 mg/kg every 2 weeks escalating up to a maximum dose of 15 mg/kg.
  arm group label: Phase 1b Ovarian Cancer
  arm group type: Experimental
  description: IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.
  arm group label: Phase 1b Colorectal Cancer
  arm group type: Experimental
  description: IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.
  arm group label: Phase 1b Triple-negative Breast Cancer
  arm group type: Experimental
  description: IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.
  arm group label: Phase 1b Bladder Cancer
  arm group type: Experimental
  description: IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.
  arm group label: Phase 1b Gastric or Esophageal Cancer
  arm group type: Experimental
  description: IMGS-001 will be administered every 2 weeks at the highest of the two doses of IMGS-001 that were selected for further evaluation in Phase 1a. Based on meeting minimum prespecified efficacy criteria, additional subjects may be enrolled and randomly assigned (1:1) to receive either the higher dose (Arm A) or a lower dose (Arm B) selected from Phase 1a.
  intervention type: Drug
  intervention name: IMGS-001
  description: Every 2 weeks
  arm group label: Phase 1a Solid Tumors
  arm group label: Phase 1b Bladder Cancer
  arm group label: Phase 1b Colorectal Cancer
  arm group label: Phase 1b Gastric or Esophageal Cancer
  arm group label: Phase 1b Ovarian Cancer
  arm group label: Phase 1b Triple-negative Breast Cancer
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Charles Schweizer, PhD
  phone: 346-772-0336
  email: charles.schweizer@immunogenesis.com
  facility: 
  status: Recruiting
  contact: 
  investigator: 
  country: United States
  responsible party type: Sponsor
  mesh term: Neoplasms
  sharing ipd: No